Madrigal Surges 5.84 on 212.79 Volume Spike as FDA Approves Wegovy for MASH Triggering Competitive Market Shift

Madrigal Pharmaceuticals (NASDAQ:MDGL) surged 5.84% on August 18, 2025, with a trading volume of $0.30 billion—a 212.79% increase from the previous day—ranking 314th in market activity. The stock’s performance coincided with regulatory developments in the MASH (metabolic dysfunction-associated steatohepatitis) treatment landscape, where the FDA approved Novo Nordisk’s Wegovy for addressing noncirrhotic MASH with moderate to advanced liver fibrosis. This milestone positions Wegovy as the first glucagon-like peptide-1 (GLP-1) receptor agonist approved for the condition, introducing a competitive dynamic for Madrigal’s Rezdiffra, its primary MASH therapy. Analysts noted that Wegovy’s efficacy in resolving steatohepatitis and improving liver fibrosis could reshape treatment protocols, though some suggest combination therapies with Rezdiffra may enhance outcomes. Madrigal’s shares have rallied over 29% this month, reflecting investor optimism about its market potential despite the new regulatory entrant.

Analysts highlighted the potential for polypharmacy in MASH management, with Wegovy’s broad metabolic benefits complementing other mechanisms of action like Madrigal’s thyroid hormone receptor beta agonist. BMO analyst Evan David Seigerman emphasized that Wegovy’s clean safety profile and proven efficacy could establish it as a foundational treatment, while other therapies might serve as add-ons for optimized results. Leerink Partners’ Thomas Smith observed that Rezdiffra’s existing patient base—over 23,000 within a year of launch—represents a fraction of the estimated 315,000 MASH-affected population, suggesting room for growth even amid competition. Smith also noted that Wegovy’s approval could improve MASH diagnosis rates by expanding reimbursement pathways beyond weight management, potentially broadening the market for MASH therapies.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to now delivered moderate returns. The CAGR was 6.98%, with a maximum drawdown of 15.46% during the backtest period. The strategy demonstrated steady growth over time, making it a robust choice for investors seeking consistent returns. However, the significant drawdown in mid-2023 highlights the importance of risk management in high-volume trading strategies.